No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial
Open Access
- 30 March 2010
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 10 (1) , 18
Abstract
Right ventricular dilatation in the setting of acute pulmonary embolism is associated with an adverse prognosis. Treatment with a pulmonary vasodilator has never been studied systematically. We evaluated the effect of epoprostenol on right ventricular diameter and function in patients with acute pulmonary embolism and right ventricular dilatation.Keywords
This publication has 36 references indexed in Scilit:
- Critical Appraisal on the Utility of Echocardiography in the Management of Acute Pulmonary EmbolismCardiology in Review, 2010
- Right Ventricular Systolic Function Is Not the Sole Determinant of Tricuspid Annular MotionThe American Journal of Cardiology, 2006
- Prostacyclin for pulmonary hypertension in adultsCochrane Database of Systematic Reviews, 2005
- Heparin plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary EmbolismNew England Journal of Medicine, 2002
- Regression of right ventricular hypokinesis after thrombolysis in acute pulmonary embolismThe American Journal of Cardiology, 1996
- The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolismIntensive Care Medicine, 1996
- Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusionThe Lancet, 1993
- Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activatorJACC, 1987
- Continuous wave doppler determination of right ventricular pressure: A simultaneous Doppler-catheterization study in 127 patientsJACC, 1985
- Thromboxane Mediation of Cardiopulmonary Effects of EmbolismJournal of Clinical Investigation, 1982